The manufacturing of the drug will be retained by TJ Biopharma at its site in Hangzhou, which would make felzartamab China’s ...
Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.
Biogen (NASDAQ:BIIB) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the ...
Biogen (BIIB) has reached a deal worth up to $850M with TJ Bio to acquire exclusive rights in Greater China for felzartamab, an antibody therapy designed to target various immune-mediated disorders, ...
Biogen (NASDAQ:BIIB | BIIB Price Prediction) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst ...
Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights ...
4don MSN
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma
April 20 (Reuters) - Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater ...
Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease medicines.
Biogen has agreed to pay up to $850 million to acquire TJ Bio's exclusive rights to felzartamab in the Greater China region, giving it worldwide rights to the investigational drug that is currently in ...
'Mad Money' host Jim Cramer weighs in on stocks including: AES, InterDigital, Infleqtion, Netskope, and Biogen.
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner -- Advancing felzartamab -- a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results